310 related articles for article (PubMed ID: 35957826)
1. Biochemical Diagnosis of Catecholamine-Producing Tumors of Childhood: Neuroblastoma, Pheochromocytoma and Paraganglioma.
Eisenhofer G; Peitzsch M; Bechmann N; Huebner A
Front Endocrinol (Lausanne); 2022; 13():901760. PubMed ID: 35957826
[TBL] [Abstract][Full Text] [Related]
2. Clinical diagnosis of pheochromocytoma and paraganglioma-induced secondary hypertension through UPLC-MS/MS analysis of plasma catecholamines and their metabolites.
Zhang W; Li X; Li W; Zhang Y; Cai J; Feng S; Sun Z
J Clin Hypertens (Greenwich); 2024 Apr; 26(4):416-424. PubMed ID: 38459755
[TBL] [Abstract][Full Text] [Related]
3. Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option?
Peitzsch M; Kaden D; Pamporaki C; Langton K; Constantinescu G; Conrad C; Fliedner S; Sinnott RO; Prejbisz A; Därr R; Lenders JWM; Bursztyn M; Eisenhofer G
Eur J Endocrinol; 2020 May; 182(5):499-509. PubMed ID: 32187575
[TBL] [Abstract][Full Text] [Related]
4. Biochemical Assessment of Pheochromocytoma and Paraganglioma.
Eisenhofer G; Pamporaki C; Lenders JWM
Endocr Rev; 2023 Sep; 44(5):862-909. PubMed ID: 36996131
[TBL] [Abstract][Full Text] [Related]
5. Urinary Free Metanephrines for Diagnosis of Pheochromocytoma and Paraganglioma.
Ahn J; Park JY; Kim G; Jin SM; Hur KY; Lee SY; Kim JH
Endocrinol Metab (Seoul); 2021 Jun; 36(3):697-701. PubMed ID: 34107605
[TBL] [Abstract][Full Text] [Related]
6. Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: Particular importance for early infancy.
Peitzsch M; Mangelis A; Eisenhofer G; Huebner A
Clin Chim Acta; 2019 Jul; 494():100-105. PubMed ID: 30904545
[TBL] [Abstract][Full Text] [Related]
7. Stability and reference intervals of spot urinary fractionated metanephrines and methoxytyramine by tandem mass spectrometry as a screening method for pheochromocytoma and paraganglioma.
Wang K; Gao X; Cong H; Zhang W; Shi X; Dai S; Zhou Z
Endocrine; 2020 Jul; 69(1):188-195. PubMed ID: 32222878
[TBL] [Abstract][Full Text] [Related]
8. Biochemical testing for neuroblastoma using plasma free 3-O-methyldopa, 3-methoxytyramine, and normetanephrine.
Peitzsch M; Butch ER; Lovorn E; Mangelis A; Furman WL; Santana VM; Hero B; Berthold F; Shulkin BL; Huebner A; Eisenhofer G
Pediatr Blood Cancer; 2020 Feb; 67(2):e28081. PubMed ID: 31724812
[TBL] [Abstract][Full Text] [Related]
9. Properly Collected Plasma Metanephrines Excludes PPGL After False-Positive Screening Tests.
Kline GA; Boyd J; Polzin B; Harvey A; Pasieka JL; Sadrzadeh HSM; Leung AA
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2900-e2906. PubMed ID: 33846745
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors.
Procopiou M; Finney H; Akker SA; Chew SL; Drake WM; Burrin J; Grossman AB
Eur J Endocrinol; 2009 Jul; 161(1):131-40. PubMed ID: 19383804
[TBL] [Abstract][Full Text] [Related]
11. [Clinical profile of pheochromocytoma and paraganglioma with normal plasma free metanephrines].
Liu L; Tian J; Wu K; Gao Y; Zhang Z; Zhang JQ; Guo XH
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Aug; 52(4):614-620. PubMed ID: 32773788
[TBL] [Abstract][Full Text] [Related]
12. Performance of plasma free metanephrines in diagnosis of pheochromocytomas and paragangliomas in the population of Asturias.
Martínez-Morillo E; Valdés Gallego N; Eguia Ángeles E; Fernández Fernández JC; Prieto García B; Álvarez FV
Endocrinol Diabetes Nutr (Engl Ed); 2019 May; 66(5):312-319. PubMed ID: 30391255
[TBL] [Abstract][Full Text] [Related]
13. Addition of 3-methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: Which is the best diagnostic strategy.
Liu L; Xie W; Song Z; Wang T; Li X; Gao Y; Li Y; Zhang J; Guo X
Clin Endocrinol (Oxf); 2022 Feb; 96(2):132-138. PubMed ID: 34486152
[TBL] [Abstract][Full Text] [Related]
14. Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated
Eisenhofer G; Prejbisz A; Peitzsch M; Pamporaki C; Masjkur J; Rogowski-Lehmann N; Langton K; Tsourdi E; Pęczkowska M; Fliedner S; Deutschbein T; Megerle F; Timmers HJLM; Sinnott R; Beuschlein F; Fassnacht M; Januszewicz A; Lenders JWM
Clin Chem; 2018 Nov; 64(11):1646-1656. PubMed ID: 30097498
[TBL] [Abstract][Full Text] [Related]
15. Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases.
Kawashima A; Sone M; Inagaki N; Okamoto K; Tsuiki M; Izawa S; Otsuki M; Okamura S; Ichijo T; Katabami T; Takeda Y; Yoshimoto T; Naruse M; Tanabe A
Endocrine; 2021 Oct; 74(1):155-162. PubMed ID: 34272648
[TBL] [Abstract][Full Text] [Related]
16. ACCURACY OF PLASMA FREE METANEPHRINES IN THE DIAGNOSIS OF PHEOCHROMOCYTOMA AND PARAGANGLIOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS.
Chen Y; Xiao H; Zhou X; Huang X; Li Y; Xiao H; Cao X
Endocr Pract; 2017 Oct; 23(10):1169-1177. PubMed ID: 28704098
[TBL] [Abstract][Full Text] [Related]
17. Performance of plasma fractionated free metanephrines by enzyme immunoassay in the diagnosis of pheochromocytoma and paraganglioma in children.
Sarathi V; Pandit R; Patil VK; Lia AR; Bandgar TR; Shah NS
Endocr Pract; 2012; 18(5):694-9. PubMed ID: 22982790
[TBL] [Abstract][Full Text] [Related]
18. Plasma Metabolome Profiling for the Diagnosis of Catecholamine Producing Tumors.
März J; Kurlbaum M; Roche-Lancaster O; Deutschbein T; Peitzsch M; Prehn C; Weismann D; Robledo M; Adamski J; Fassnacht M; Kunz M; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():722656. PubMed ID: 34557163
[TBL] [Abstract][Full Text] [Related]
19. Comparison of plasma metanephrines measured by a commercial immunoassay and urinary catecholamines in the diagnosis of pheochromocytoma.
Christensen TT; Frystyk J; Poulsen PL
Scand J Clin Lab Invest; 2011 Dec; 71(8):695-700. PubMed ID: 22023043
[TBL] [Abstract][Full Text] [Related]
20. Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma.
Eisenhofer G; Deutschbein T; Constantinescu G; Langton K; Pamporaki C; Calsina B; Monteagudo M; Peitzsch M; Fliedner S; Timmers HJLM; Bechmann N; Fankhauser M; Nölting S; Beuschlein F; Stell A; Fassnacht M; Prejbisz A; Lenders JWM; Robledo M
Clin Chem Lab Med; 2020 Oct; 59(2):353-363. PubMed ID: 33001846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
